Therapeutic Eye Injections May Be Needed Less Often
Johns Hopkins MedicineBiomedical engineers have created a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur. The team gave the drug a biodegradable coating to keep it in the eye longer. If effective in humans, monthly needle sticks to the eye, which are the current standard of care, could be replaced with only two or three injections per year.